<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35307817</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1600-0404</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>145</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Acta neurologica Scandinavica</Title>
          <ISOAbbreviation>Acta Neurol Scand</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comment on comorbidities in older patients with myasthenia gravis.</ArticleTitle>
        <Pagination>
          <StartPage>789</StartPage>
          <EndPage>790</EndPage>
          <MedlinePgn>789-790</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ane.13606</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Galassi</LastName>
            <ForeName>Giuliana</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-8775-0415</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical, Metabolic Neural Sciences, University of Modena, Modena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Denmark</Country>
        <MedlineTA>Acta Neurol Scand</MedlineTA>
        <NlmUniqueID>0370336</NlmUniqueID>
        <ISSNLinking>0001-6314</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Acta Neurol Scand. 2022 Mar;145(3):371-374</RefSource>
          <PMID Version="1">34750811</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">immunology</Keyword>
        <Keyword MajorTopicYN="Y">myasthenia gravis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35307817</ArticleId>
        <ArticleId IdType="doi">10.1111/ane.13606</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Klimiec-Moskal E, Quirke M, Leite MI. Comorbidities in older patients with myasthenia gravis - comparison between early- and late-onset disease. Acta Neurol Scand. 2021;145(3):371-374. doi:10.1111/ane.13549</Citation>
        </Reference>
        <Reference>
          <Citation>Deymeer F. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG. Acta Myol. 2020;39:345-352. doi:10.36185/2532-1900-038</Citation>
        </Reference>
        <Reference>
          <Citation>Li Y, Dong X, Li Z, et al. Characteristics of myasthenia gravis in elderly patients: a retrospective study. Neurol Sci. 2021. doi: 10.1007/s10072-021-05599-z</Citation>
        </Reference>
        <Reference>
          <Citation>Cortés-Vicente E, Álvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94(11):e1171-e1180. doi:10.1212/WNL.0000000000008903</Citation>
        </Reference>
        <Reference>
          <Citation>Melzer N, Ruck T, Gold R, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263:1473-1494. doi:10.1007/s00415-016-8045-z</Citation>
        </Reference>
        <Reference>
          <Citation>Murthy JMK. Myasthenic crisis - comorbidities, complications, long-term outcomes: the challenges. Ann Indian Acad Neurol. 2019;22:472-473. doi:10.4103/aian.AIAN_472_19</Citation>
        </Reference>
        <Reference>
          <Citation>Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023-1036. doi:10.1016/S1474-4422(15)</Citation>
        </Reference>
        <Reference>
          <Citation>Vijayan J, Menon D, Barnett C, et al. Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis. Muscle Nerve. 2021;64:462-466. doi:10.1002/mus.27369</Citation>
        </Reference>
        <Reference>
          <Citation>Misra UK, Kalita J, Singh VK, Kumar S. A study of comorbidities in myasthenia gravis. Acta Neurol Belg. 2020;120:59-64. doi:10.1007/s13760-019-01102-w</Citation>
        </Reference>
        <Reference>
          <Citation>Vadasz Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. BMC Med. 2013;11:94. doi:10.1186/1741-7015-11-94</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
